GCG and Hypoglycemia: In conclusion, the results of this study demonstrate that daily SSTR2a administration increases endogenous glucagon secretion, reducing overall hypoglycemia exposure, and that these effects may be limited in this model by factors including effects of antecedent hypoglycemia and due to overall improvement of glycemic status and glucagon counterregulatory capability of the rats over time.